TSE:FRX Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis C$6.40 +0.03 (+0.47%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades About Fennec Pharmaceuticals Stock (TSE:FRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fennec Pharmaceuticals alerts:Sign Up Key Stats Today's RangeC$6.40▼C$6.6950-Day RangeC$5.76▼C$8.6252-Week RangeC$5.76▼C$15.43Volume500 shsAverage Volume1,887 shsMarket CapitalizationC$175.10 millionP/E Ratio64.00Dividend Yield2.02%Price TargetN/AConsensus RatingN/A Company OverviewFennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Read More… Musk’s new company could top a trillion? (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. Receive FRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address FRX Stock News HeadlinesFennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov Sells 2,431 SharesOctober 5, 2024 | insidertrades.comFennec Pharmaceuticals Inc.September 5, 2024 | wsj.comElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.October 17, 2024 | Porter & Company (Ad)Fennec Pharmaceuticals Inc (FRX)August 16, 2024 | investing.comFennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.deFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comFennec Pharma Names Hackman CEOAugust 5, 2024 | markets.businessinsider.comFennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 14, 2024 | finanznachrichten.deSee More Headlines FRX Stock Analysis - Frequently Asked Questions How have FRX shares performed this year? Fennec Pharmaceuticals' stock was trading at C$15.16 at the start of the year. Since then, FRX stock has decreased by 57.8% and is now trading at C$6.40. View the best growth stocks for 2024 here. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc. (TSE:FRX) issued its quarterly earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.35. The biopharmaceutical company earned $9.94 million during the quarter, compared to the consensus estimate of $18.67 million. Fennec Pharmaceuticals had a negative trailing twelve-month return on equity of 1,005.59% and a net margin of 5.59%. How do I buy shares of Fennec Pharmaceuticals? Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Tilray (TLRY), Aurora Cannabis (ACB), Encanto Potash (EPO), Fennec Pharmaceuticals (FENC), Ocugen (OCGN), Passport Potash (PPI) and Workhorse Group (WKHS). Company Calendar Last Earnings8/13/2024Today10/17/2024Next Earnings (Estimated)11/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolTSE:FRX CUSIPN/A CIKN/A Webfennecpharma.com Phone+1-919-6364530FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.10 Trailing P/E Ratio64.00 Forward P/E Ratio10.60 P/E GrowthN/ANet IncomeC$2.73 million Net Margins5.59% Pretax MarginN/A Return on Equity-1,005.59% Return on Assets8.88% Debt Debt-to-Equity Ratio1,040.68 Current Ratio8.02 Quick Ratio10.17 Sales & Book Value Annual SalesC$48.89 million Price / Sales3.58 Cash FlowC$0.55 per share Price / Cash Flow11.66 Book ValueC($0.05) per share Price / Book-128.00Miscellaneous Outstanding Shares27,360,000Free FloatN/AMarket CapC$175.10 million OptionableNot Optionable Beta0.25 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (TSE:FRX) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.